Skip to main content
    C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $78.94
    -5.84 (-6.89%)

    Market Cap: $7.57B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    CG Oncology, Inc. Common stock (CGON) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CG Oncology, Inc. Common stock (CGON) has a market cap of $7.57B and an enterprise value of $7.55B. It kept -3851.09% of revenue as net income over the last 12 months. Revenue grew 169.85% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 0.33% below the market cap, as cash exceeds debt.

    Market Cap$7.57B
    Enterprise Value$7.55B
    Latest price (Nov 17, 2026)$78.94

    Key Dates

    The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 25, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.76% in the quarter ended Sep 30, 2026 and grew 15.05% a year over 2 years.

    Shares Outstanding88.87M
    Shares Change (YoY)+15.82%
    Shares Change (QoQ)+0.76%
    Share Count Growth (2Y CAGR)+15.05%

    Valuation Ratios

    P/B Ratio7.1x
    P/TBV Ratio7.2x

    Price Statistics

    The stock is up 92.49% over 52 weeks and trades 15.49% above its 50-day average.

    Beta (1Y)0.94
    52-Week Change+92.49%
    1-Month Change+31.65%
    3-Month Change-2.16%
    6-Month Change+24.71%
    Total Return (1Y)+92.49%
    Return vs SPY (1Y)+73.96%
    Max Drawdown (1Y)-27.41%
    Max Drawdown (3Y)-67.47%
    Sharpe Ratio (1Y)1.08
    Correlation with SPY (1Y)0.22
    50-Day Average$68.35
    200-Day Average$66.96
    52-Week Range$37.01 to $93.95
    RSI (14 Days)61.7
    Average Volume (20 Days)1.76M

    Price chart

    Financial Position

    Current assets cover 21.70x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio21.70x
    Quick Ratio21.68x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -21.06% and return on equity is -23.96% over the last 12 months.

    Return on Equity (ROE)-23.96%
    Return on Assets (ROA)-22.69%
    Return on Invested Capital (ROIC)-21.06%
    ROA (5Y Average)-20.45%
    Asset Turnover0.01x
    Inventory Turnover11.65x
    Receivables Turnover11.39x
    Cash Conversion Cycle-262 days

    Scores

    CGON has an Altman Z-Score of 75.07, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score75.07
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $6.17M over the last 12 months.

    Revenue$6.17M
    Revenue Growth (YoY)+169.85%
    Gross Profit-$6.46M
    Operating Income-$264.74M
    Pretax Income-$237.46M
    Net Income-$237.46M
    Reported EPS (TTM)-$2.76

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 94.38% of the $1.05B in total assets.

    Cash and Equivalents$28.25M
    Total Debt$3.00M
    Net Cash$25.25M
    Net Cash Per Share$0.28
    Working Capital$961.30M
    Shareholder Equity$990.97M
    Book Value Per Share$11.15
    Tangible Book Value$980.14M
    Tangible Book Per Share$11.03
    Total Assets$1.05B
    Total Liabilities$55.70M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.89M of capital spending, operating cash flow left -$189.17M of free cash flow.

    Operating Cash Flow-$187.28M
    Capital Expenditures$1.89M
    Free Cash Flow-$189.17M
    FCF Per Share-$2.13
    Depreciation and Amortization$4.65M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4293.53%.

    Gross Margin-104.77%
    Operating Margin-4293.53%
    Pretax Margin-3851.09%
    Net Margin-3851.09%
    FCF Margin-3068.02%
    Gross Margin (5Y Average)75.41%

    Dividends and Yields

    CGON does not pay a dividend. Its free cash flow yield is -2.70%.

    FCF Yield-2.70%
    Buyback Yield-6.98%
    Shareholder Yield-6.98%

    Peer Position

    Against 5 similar companies, CGON has the 2nd highest ROIC.

    ROIC-21.06% vs -65.96% median
    Revenue Growth (Trailing 4 Quarters, YoY)+169.85% vs +49.45% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 384.46% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+384.46%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CGON

    What is CGON's market cap?

    CG Oncology, Inc. Common stock has a market cap of $7.57B. Its enterprise value, which adds debt and subtracts cash, is $7.55B.

    How many shares of CGON are outstanding?

    CG Oncology, Inc. Common stock has 88.87M shares outstanding. The count is up 15.82% from a year earlier.

    Does CGON pay a dividend?

    No. CG Oncology, Inc. Common stock does not pay a dividend.

    How much debt does CGON have?

    CG Oncology, Inc. Common stock has $3.00M of total debt and $28.25M of cash and equivalents, a net cash position of $25.25M.